Список литературы

27. Burrus T.M., Wijdicks E.F., Rabinstein A.A. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology. 2009;73(1):66–70. DOI:10.1212/WNL.0B013E3181AAEA1B.

28. Alwan F., Vendramin C., Vanhoorelbeke K., et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466–71. DOI:10.1182/BLOOD-2016-12-758656.

29. Zafrani L., Mariotte E., Darmon M., et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost. 2015;13(3):380–9. DOI:10.1111/JTH.12826.

30. Wahla A.S., Ruiz J., Noureddine N., et al. Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review. Eur J Haematol. 2008;81(4):311–6. DOI:10.1111/J.1600-0609.2008.01112.X.

31. Griffin D., Al-Nouri Z.L., Muthurajah D., et al. First symptoms in patients with thrombotic thrombocytopenic purpura (TTP): what are they and when do they occur? Transfusion. 2013;53(1):235. DOI:10.1111/J.1537-2995.2012.03934.X.

32. Muñiz A.E., Barbee R.W. Thrombotic thrombocytopenic purpura (TTP) presenting as pancreatitis. J Emerg Med. 2003;24(4):407–11. DOI:10.1016/S0736-4679(03)00038-6.

33. Fox L.C., Cohney S.J., Kausman J.Y., et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 2018;48(6):624–36. DOI:10.1111/IMJ.13804.

34. Scully M., Hunt B.J., Benjamin S., et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–35. DOI:10.1111/J.1365-2141.2012.09167.X.

35. Aksay E., Kiyan S., Ersel M., et al. Thrombotic thrombocytopenic purpura mimicking acute ischemic stroke. Emerg Med J. 2006;23(9):e51. DOI:10.1136/EMJ.2006.036327.

36. Филатов Л.Б., Томилов А.Ф., Алексеева Т.А. Гемолитическая анемия, вызванная фрагментацией эритроцитов. Клиническая онкогематология. 2011;4(4):346–55.

37. Klein P.J., Pullmann H., Féaux de Lacroix W., et al. Quantitative Bestimmung fragmentierter Erythrocyten (Schistocyten) bei Normalpersonen sowie bei operierten Patienten. Klin Wochenschr. 1975;53(18):847–51. DOI:10.1007/BF01466957.

38. Burns E.R., Lou Y., Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75(1):18–21. DOI:10.1002/AJH.10450.

39. Zini G., D’Onofrio G., Briggs C., et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Lab Hematol. 2012;34(2):107–16. DOI:10.1111/J.1751-553X.2011.01380.X.

40. Uderzo C.C., Jodele S., Eli Missiry M., et al. Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consensus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA Patients to Treat and When? J Bone Marrow Res. 2014;2(3):10000152. DOI:10.4172/2329-8820.1000152.

41. Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood. 2013;121(1):38–47. DOI:10.1182/blood-2012-08-448944.

42. Matsumoto M., Fujimura Y., Wada H., et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol. 2017;106(1):3–15. DOI:10.1007/S12185-017-2264-7.

43. Ayanambakkam A., Kremer Hovinga J.A., Vesely S.K., et al. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20. Am J Hematol. 2017;92(11):E644–6. DOI:10.1002/AJH.24885.

44. Thomas M.R., Robinson S., Scully M.A. How we manage thrombotic microangiopathies in pregnancy. Br J Haematol. 2016;173(6):821–30. DOI:10.1111/bjh.14045.

45. Ferrari S., Scheiflinger F., Rieger M., et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood. 2007;109(7):2815–22. DOI:10.1182/BLOOD-2006-02-006064.

46. Shelat S.G., Smith P., Ai J., et al. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo. J Thromb Haemost. 2006;4(8):1707–17. DOI:10.1111/J.1538-7836.2006.02025.X.

47. Sarode R., Bandarenko N., Brecher M.E., et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher. 2014;29(3):148–67. DOI:10.1002/JCA.21302.

48. Knöbl P. Thrombotic thrombocytopenic purpura. Memo. 2018;11(3):220–6. DOI:10.1007/S12254-018-0429-6.

49. Zheng X. Structure-function and regulation of ADAMTS13. J Thromb Haemost. 2013;11(Suppl 1):11–23. DOI:10.1111/jth.12221.

50. Rock G., Anderson D., Clark W., et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol. 2005;129(1):79–86. DOI:10.1111/J.1365-2141.2005.05418.X.

51. Joly B.S., Coppo P., Veyradier A. Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol. 2018;101(4):425–34. DOI:10.1111/ejh.13107.

52. Галстян Г.М., Гапонова Т.В., Шерстнев Ф.С. Клиническое использование криосупернатантной плазмы. Гематология и трансфузилогия. 2020;65(3):351–9.

53. Freedman M., Rock G. Analysis of the products of cryoprecipitation: RiCoF is deficient in cryosupernatant plasma. Transfus Apher Sci. 2010;43(2):179–82. DOI:10.1016/J.TRANSCI.2010.07.004.

54. Picod A., Coppo P. When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Transfus Apher Sci. 2019;58(3):273–7. DOI:10.1016/J.TRANSCI.2019.04.012.

55. Zheng X.L., Vesely S.K., Cataland S.R., et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–502. DOI:10.1111/JTH.15010.

56. Nguyen T.C., Han Y.Y. Plasma exchange therapy for thrombotic microangiopathies. Organogenesis. 2011;7(1):28–31. DOI:10.4161/ORG.7.1.14027.

57. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):81. DOI:10.1056/NEJM199108083250604.

58. Henon P. Thrombotic thrombocytopenic purpura: Clinical results of a French controlled trial. Transfus Sci. 1992;13(1):63–72. DOI:10.1016/0955-3886(92)90123-X.

59. von Baeyer H. Plasmapheresis in thrombotic microangiopathy-associated syndromes: review of outcome data derived from clinical trials and open studies. Ther Apher. 2002;6(4):320–8. DOI:10.1046/J.1526-0968.2002.00390.X.

60. Rock G., Shumak K.H., Sutton D.M., et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol. 1996;94(2):383–6. DOI:10.1046/J.1365-2141.1996.D01-1800.X.

61. Mazepa M.A., Raval J.S., Brecher M.E., et al. Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise. J Clin Apher. 2018;33(3):291–6. DOI:10.1002/JCA.21600.

62. Altuntas F., Aydogdu I., Kabukcu S., et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci. 2007;36(1):57–67. DOI:10.1016/J.TRANSCI.2006.05.014.

63. Zeigler Z.R., Shadduck R.K., Gryn J.F., et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher. 2001;16(1):19–22. DOI:10.1002/JCA.1003.

64. Lin Q., Fan L., Huang H., et al. Combination of Fresh Frozen Plasma and Cryosupernatant Plasma for Therapeutic Plasma Exchange in Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Biomed Res Int. 2019;2019. DOI:10.1155/2019/1756109.

65. Moake J.L., Byrnes J.J., Troll J.H., et al. Effects of fresh-frozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1985;65(5):1232–6.

66. Stefanello B., De Paula E.V., Andrade Orsi F., et al. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation. J Clin Apher. 2014;29(6):311–5. DOI:10.1002/JCA.21336.

67. Raife T.J., Friedman K.D., Dwyre D.M. The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma. Transfusion. 2006;46(1):74–9. DOI:10.1111/J.1537-2995.2005.00674.X.

68. Rock G., Ahluwalia N., Anderson D. Metalloprotease levels are variably altered in thrombotic thrombocytopenic patients at presentation and after plasma exchange with either cryosupernatant plasma or fresh frozen plasma. Blood. 2001;102:539a.

69. Thejeel B., Garg A.X., Clark W.F., et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review. Am J Hematol. 2016;91(6):623–30. DOI:10.1002/AJH.24339.

70. Sayani F.A., Abrams C.S. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860–7. DOI:10.1182/BLOOD-2014-11-551580.

71. Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325(6):398–403. DOI:10.1056/NEJM199108083250605.

72. Toyoshige M., Zaitsu Y., Okafuji K., et al. Successful treatment of thrombotic thrombocytopenic purpura with high‐dose corticosteroid. Vol. 41, Am J Hematol. Am J Hematol; 1992. p. 69. DOI:10.1002/ajh.2830410119.

73. Balduini C.L., Gugliotta L., Luppi M., et al. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol. 2010;89(6):591–6. DOI:10.1007/S00277-009-0877-5.

74. Rojnuckarin P., Watanaboonyongcharoen P., Akkawat B., et al. The role of pulse dexamethasone in acquired idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006;4(5):1148–50. DOI:10.1111/J.1538-7836.2006.01879.X.

75. George J.N., Woodson R.D., Kiss J.E., et al. Rituximab Therapy for Thrombotic Thrombocytopenic Purpura: A Proposed Study of the Transfusion Medicine/Hemostasis Clinical Trials Network With a Systematic Review of Rituximab Therapy for Immune-Mediated Disorders. J Clin Apher. 2006;21:49–56. DOI:10.1002/jca.20091.

76. Regazzi M.B., Iacona I., Avanzini M.A., et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit. 2005;27(6):785–92. DOI:10.1097/01.FTD.0000184162.60197.C1.

77. Tobinai K., Igarashi T., Itoh K., et al. Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann Oncol Off J Eur Soc Med Oncol. 2004;15(5):821–30. DOI:10.1093/ANNONC/MDH176.

78. Chen H., Fu A., Wang J., et al. Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253–60. DOI:10.1177/0300060517695646.

79. McDonald V., Manns K., Mackie I.J., et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. DOI:10.1111/J.1538-7836.2010.03818.X.

80. Westwood J.P., Thomas M., Alwan F., et al. Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv. 2017;1(15):1159–66. DOI:10.1182/BLOODADVANCES.2017008268.